2005PubMedRequires access

[Down-regulation of caveolin-1 in gastric carcinoma and its clinical biological significance].

Xue Gao, Yuan Sun, Lei Huang, Xiao-Yan Chen, Kaili Zhang, Qing‐You Kong, Jia Liu, Hong Li

Open publisher page 8 citations

Abstract

BACKGROUND & OBJECTIVE: Caveolin-1, a candidate tumor suppressor gene, aberrantly expressed in many kinds of carcinomas. This research was designed to check the expression of Caveolin-1 in non-cancerous gastric mucosa, intestinal metaplasia, atypical hyperplasia, gastric cancer tissues, and gastric cancer cell lines MGC803 and BGC823, and to analyze its clinical biological significance in stepwise gastric carcinogenesis. METHODS: Frozen gastric tissue array-based immunohistochemistry (IHC) was used to examine the expression of Caveolin-1 in 56 specimens of gastric cancer, 29 specimens of non-cancerous mucosa, 11 specimens of intestinal metaplasia, and 7 specimens of atypical hyperplasia. Correlations of Caveolin-1 expression to clinical stage, lymph node metastasis, Lauren's type, and histological type were analyzed. Reverse transcription-polymerase chain reaction (RT-PCR) and Western blot were used to detect mRNA and protein levels of Caveolin-1 in 56 specimens of gastric cancer and relevant adjuvant non-cancerous tissue, and cell lines MGC803 and BGC823. RESULTS: Positive rate of Caveolin-1 was significantly lower in gastric cancer than in non-cancerous mucosa, intestinal metaplasia, and atypical hyperplasia (17.9% vs. 84.8%, 81.8%, and 57.1%, P<0.05). Positive rate of Caveolin-1 was lower in advanced gastric cancers than in gastric cancer of early stage (16.0% vs. 33.3%), but the difference was not significant (P>0.05). Positive rate of Caveolin-1 was significantly lower in diffuse gastric cancer than in gastric cancer of intestinal type (7.0% vs. 26.9%, P<0.05), significantly lower in the cases with lymph node metastases than in the cases without lymph node metastases (9.7% vs. 31.8%, P<0.05). Protein and mRNA levels of Caveolin-1 in gastric cancer and relevant adjuvant non-cancerous tissues have no significant difference, but its expression was low in MGC803 and BGC823 cells. CONCLUSION: Progressive down-regulation of Caveolin-1 in gastric epithelial cells is correlated to gastric carcinogenesis.

About this research paper

What this paper is about

BACKGROUND & OBJECTIVE: Caveolin-1, a candidate tumor suppressor gene, aberrantly expressed in many kinds of carcinomas. This research was designed to check the expression of Caveolin-1 in non-cancerous gastric mucosa, intestinal metaplasia, atypical hyperplasia, gastric cancer tissues, and gastric cancer cell lines MGC803 and BGC823, and to analyze its clinical biological significance in stepwise gastric carcinogenesis. METHODS: Frozen gastric tissue array-based immunohistochemistry (IHC) was used to examine the expression of Caveolin-1 in 56 specimens of gastric cancer, 29 specimens of non-cancerous mucosa, 11 specimens of intestinal metaplasia, and 7 specimens of atypical hyperplasia. Correlations of Caveolin-1 expression to clinical stage, lymph node metastasis, Lauren's type, and histological type were analyzed. Reverse transcription-polymerase chain reaction (RT-PCR) and Western blot were used to detect mRNA and protein levels of Caveolin-1 in 56 specimens of gastric cancer and relevant adjuvant non-cancerous tissue, and cell lines MGC803 and BGC823. RESULTS: Positive rate of Caveolin-1 was significantly lower in gastric cancer than in non-cancerous mucosa, intestinal metaplasia, and atypical hyperplasia (17.9% vs. 84.8%, 81.8%, and 57.1%, P<0.05). Positive rate of Caveolin-1 was lower in advanced gastric cancers than in gastric cancer of early stage (16.0% vs. 33.3%), but the difference was not significant (P>0.05). Positive rate of Caveolin-1 was significantly lower in diffuse gastric cancer than in gastric cancer of intestinal type (7.0% vs. 26.9%, P<0.05), significantly lower in the cases with lymph node metastases than in the cases without lymph node metastases (9.7% vs. 31.8%, P<0.05). Protein and mRNA levels of Caveolin-1 in gastric cancer and relevant adjuvant non-cancerous tissues have no significant difference, but its expression was low in MGC803 and BGC823 cells. CONCLUSION: Progressive down-regulation of Caveolin-1 in gastric epithelial cells is correlated to gastric carcinogenesis.

Why it matters

OpenAlex reports 8 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

BACKGROUND & OBJECTIVE: Caveolin-1, a candidate tumor suppressor gene, aberrantly expressed in many kinds of carcinomas. This research was designed to check the expression of Caveolin-1 in non-cancerous gastric mucosa, intestinal metaplasia, atypical hyperplasia, gastric cancer tissues, and gastric cancer cell lines MGC803 and BGC823, and to analyze its clinical biological significance in stepwise gastric carcinogenesis. METHODS: Frozen gastric tissue array-based immunohistochemistry (IHC) was used to examine the expression of Caveolin-1 in 56 specimens of gastric cancer, 29 specimens of non-cancerous mucosa, 11 specimens of intestinal metaplasia, and 7 specimens of atypical hyperplasia. Correlations of Caveolin-1 expression to clinical stage, lymph node metastasis, Lauren's type, and histological type were analyzed. Reverse transcription-polymerase chain reaction (RT-PCR) and Western blot were used to detect mRNA and protein levels of Caveolin-1 in 56 specimens of gastric cancer and relevant adjuvant non-cancerous tissue, and cell lines MGC803 and BGC823. RESULTS: Positive rate of Caveolin-1 was significantly lower in gastric cancer than in non-cancerous mucosa, intestinal metaplasia, and atypical hyperplasia (17.9% vs. 84.8%, 81.8%, and 57.1%, P<0.05). Positive rate of Caveolin-1 was lower in advanced gastric cancers than in gastric cancer of early stage (16.0% vs. 33.3%), but the difference was not significant (P>0.05). Positive rate of Caveolin-1 was significantly lower in diffuse gastric cancer than in gastric cancer of intestinal type (7.0% vs. 26.9%, P<0.05), significantly lower in the cases with lymph node metastases than in the cases without lymph node metastases (9.7% vs. 31.8%, P<0.05). Protein and mRNA levels of Caveolin-1 in gastric cancer and relevant adjuvant non-cancerous tissues have no significant difference, but its expression was low in MGC803 and BGC823 cells. CONCLUSION: Progressive down-regulation of Caveolin-1 in gastric epithelial cells is correlated to gastric carcinogenesis.

Key concepts: Intestinal metaplasia, Atypical hyperplasia, Pathology, Cancer, Immunohistochemistry, Hyperplasia, Carcinogenesis, Medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
[Down-regulation of caveolin-1 in gastric carcinoma and its clinical biological significance]. — Research Paper | ScholarLens